A Phase 3 interventional study of Sodium Fluoride (NaF) and Placebo in Dental Caries, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Sodium Fluoride in Dental Caries — none open to participants now, none under way, none of them phase 3. Sodium Fluoride · Dental Caries.
Among the 18 studies testing Sodium Fluoride in Dental Caries, this one is the 13th largest by enrollment, is the only one that started in 2008, is one of 5 in phase 3, and was the 4th registered.
1,174 studies on the registry are indexed under Dental Caries; 209 are open to participants now.
Browse Dental Caries studies →None of the 18 studies testing Sodium Fluoride in Dental Caries is open now. The open studies under Dental Caries, anywhere →
Sodium Fluoride: first FDA approval 1997 (COLGATE TOTAL). What it is approved for, and how studies give it, is on its page →
Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2008.
This study's enrollment of 65 is close to the median of 60 across 967 interventional studies indexed under Dental Caries.
Median enrollment 124 across the 18 interventional studies. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 18 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 8 studies filed under Dental Caries — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Sodium Fluoride in Dental Caries, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy of different sodium fluoride (NaF) containing toothpastes in prevention of dental caries. Change from baseline fluoride data at various time points up to four hours after a single brushing with NaF containing toothpastes will be evaluated.
Topical fluorides in a wide variety of delivery systems have been proven to be clinically effective in the prevention of dental caries. It is generally agreed that fluoride has its anti-caries effect mainly by decreasing the rate of enamel demineralization and enhancing the rate of enamel remineralization. There is a general consensus that level of fluoride in plaque fluid, may be directly related to the anti caries effects of fluoride. Also, fluoride levels in the oral fluids decrease rapidly after topical fluoride application, mainly due to the diluting and washing effect of saliva followed by periodic swallowing. To evaluate fluoride content, plaque samples will be collected from the interproximal surfaces of the posterior teeth of participants using a standardized approach. Plaque fluid fluoride will be calculated using a micro analytical method and in comparison to a standard fluoride curve constructed on the same day of the analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants brushed for one timed minute with 1.6g of NaF/silica and 0.4 percent carbopol toothpaste containing 1450ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
Drug: Sodium Fluoride (NaF)
Participants brushed for one timed minute with 1.6g of NaF toothpaste containing 1400ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
Drug: Sodium Fluoride (NaF)
Participants brushed for one timed minute with 1.6g of NaMFP/NaF toothpaste containing 1450ppmF from NaMFP and NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
Drug: Sodium Fluoride (NaF)
Participants brushed for one timed minute with 1.6g of fluoride free toothpaste. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
Drug: Placebo
Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
Also known as: fluoride
Fluoride free toothpaste (0ppmF)
Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid by Time Curve (AUC) Between 0-4 Hours
To evaluate fluoride content, plaque samples were collected from the interproximal surfaces of the posterior teeth of participants using a standardized approach. Plaque fluid fluoride were calculated using a micro analytical method and in comparison to a standard fluoride curve constructed on the same day of the analysis. AUC was determined from 0-4hours using trapezoidal rule and natural log transformation was applied due to failure of assumption of normal distribution of data.
Time frame: Plaque samples collected at 15 minutes, 30 minutes, 1 hour, 2 hours and 4 hours post single application of treatment
Natural Log Transformed AUC for Fluoride Concentration in Plaque Fluid Between 0-4 Hours
To evaluate fluoride content, plaque samples were collected from the interproximal surfaces of the posterior teeth of participants using a standardized approach. Plaque fluid fluoride were calculated using a micro analytical method and in comparison to a standard fluoride curve constructed on the same day of the analysis. AUC was determined from 0-4 hours using trapezoidal rule and natural log transformation was applied.due to failure of assumption of normal distribution of data.
Time frame: Plaque samples collected at 15 minutes, 30 minutes, 1 hour, 2 hours and 4 hours post single application of treatment
Change From Baseline in Fluoride Concentration at 15 Minutes After Brushing With Study Treatments
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
Time frame: Plaque samples were collected at baseline, 15 minutes post single application of study treatment
Change From Baseline in Fluoride Concentration at 30 Minutes Post Brushing With Study Treatments
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
Time frame: Plaque samples were collected at baseline, 30 minutes post single application of study treatment
Change From Baseline in Fluoride Concentration at 1 Hour Post Brushing With Study Treatments
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
Time frame: Plaque samples were collected at baseline, 1 hour post single application of study treatment
Change From Baseline in Fluoride Concentration at 2 Hours Post Brushing With Study Treatments
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
Time frame: Plaque samples were collected at baseline, 2 hour post single application of study treatment
Change From Baseline in Fluoride Concentration at 4 Hours Post Brushing With Study Treatments
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
Time frame: Plaque samples were collected at baseline, 4 hours post single application of study treatment
Participants were recruited at the clinical site.
| Milestone | Sodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F) | NaF Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Started | 16 | 16 | 17 | 16 |
| Completed | 15 | 16 | 16 | 14 |
| Not completed | 1 | 0 | 1 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 |
| Withdrew: Other reason | 0 | 0 | 0 | 2 |
| Milestone | Sodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F) | NaF Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Started | 15 | 15 | 16 | 15 |
| Completed | 14 | 13 | 16 | 14 |
| Not completed | 1 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Other reason | 1 | 0 | 0 | 1 |
| Milestone | Sodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F) | NaF Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Started | 15 | 14 | 14 | 14 |
| Completed | 14 | 12 | 14 | 14 |
| Not completed | 1 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 0 |
| Withdrew: Other reason | 1 | 0 | 0 | 0 |
| Milestone | Sodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F) | NaF Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Started | 12 | 14 | 14 | 14 |
| Completed | 12 | 14 | 14 | 14 |
| Not completed | 0 | 0 | 0 | 0 |
To evaluate fluoride content, plaque samples were collected from the interproximal surfaces of the posterior teeth of participants using a standardized approach. Plaque fluid fluoride were calculated using a micro analytical method and in comparison to a standard fluoride curve constructed on the same day of the analysis. AUC was determined from 0-4hours using trapezoidal rule and natural log transformation was applied due to failure of assumption of normal distribution of data.
| ln(μg*F*minutes/cm^2) | NaF Toothpaste(1450 Ppm F) | NaF Toothpaste (1400 Ppm F) |
|---|---|---|
| Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid by Time Curve (AUC) Between 0-4 Hours | 0.54 ± 0.086 | 0.54 ± 0.087 |
To evaluate fluoride content, plaque samples were collected from the interproximal surfaces of the posterior teeth of participants using a standardized approach. Plaque fluid fluoride were calculated using a micro analytical method and in comparison to a standard fluoride curve constructed on the same day of the analysis. AUC was determined from 0-4 hours using trapezoidal rule and natural log transformation was applied.due to failure of assumption of normal distribution of data.
| ln(μg*F*minutes/cm^2) | NaF Toothpaste(1450ppmF) | NaF Toothpaste (1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Natural Log Transformed AUC for Fluoride Concentration in Plaque Fluid Between 0-4 Hours | 0.54 ± 0.086 | 0.54 ± 0.087 | 0.05 ± 0.086 | -0.90 ± 0.087 |
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
| μg*F/g | NaF Toothpaste(1450ppmF) | NaF Toothpaste (1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Change From Baseline in Fluoride Concentration at 15 Minutes After Brushing With Study Treatments | 2.00 ± 4.586 | 1.56 ± 2.806 | 0.76 ± 1.633 | 0.03 ± 0.083 |
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
| μg*F/g | NaF Toothpaste(1450ppmF) | NaF Toothpaste (1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Change From Baseline in Fluoride Concentration at 30 Minutes Post Brushing With Study Treatments | 0.71 (0.0 to 7.7) | 0.72 (0.0 to 14.9) | 0.28 (0.0 to 4.7) | 0.02 (-0.3 to 0.3) |
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
| μg*F/g | NaF Toothpaste(1450ppmF) | NaF Toothpaste (1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Change From Baseline in Fluoride Concentration at 1 Hour Post Brushing With Study Treatments | 0.20 (0.0 to 3.1) | 0.22 (0.0 to 6.7) | 0.12 (0.0 to 1.6) | 0.01 (0.00 to 0.02) |
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
| μg*F/g | NaF Toothpaste(1450ppmF) | NaF Toothpaste (1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Change From Baseline in Fluoride Concentration at 2 Hours Post Brushing With Study Treatments | 0.09 (-0.1 to 0.7) | 0.09 (-0.1 to 1.0) | 0.07 (-0.3 to 0.5) | 0.00 (-0.1 to 0.1) |
Change from baseline at any time point for a treatment period was calculated as the median post brushing fluoride value at a time point minus the median baseline (pre-brushing) fluoride value for a treatment period.
| μg*F/g | NaF Toothpaste(1450ppmF) | NaF Toothpaste (1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|
| Change From Baseline in Fluoride Concentration at 4 Hours Post Brushing With Study Treatments | 0.04 (-0.1 to 0.7) | 0.04 (-0.1 to 1.2) | 0.02 (-0.3 to 0.2) | -0.01 (-0.1 to 0.1) |
Collected over All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NaF Toothpaste(1450ppmF) | — | 0/58 (0%) | 0/58 (0%) |
| NaF Toothpaste (1400ppmF) | — | 0/59 (0%) | 0/59 (0%) |
| NaMFP/NaF Toothpaste (1450ppmF) | — | 0/61 (0%) | 0/61 (0%) |
| Placebo Toothpaste (0ppmF) | — | 0/59 (0%) | 0/59 (0%) |
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 26.4 ± 6.97 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 31 |
| Male | 34 |
| Region of Enrollment(participants) | Overall Study |
|---|---|
| United States | 65 |
The record gives a start of Jun 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 4 years 8 months after primary completion. A results delay was requested in Sep 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Fluoride